Wegovy Maker to Limit Starter-Dose Supplies in U.S. as Demand Surges

Danish pharmaceuticals giant Novo Nordisk says it is adding capacity but warns supply shortfalls are likely to continue

Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth Smelov

The Danish pharmaceutical giant that makes the obesity drug Wegovy said it would temporarily hold back some lower-strength starter doses in the U.S. in an effort to safeguard supplies for current patients amid soaring demand.

The Food and Drug Administration cleared Wegovy, made by Novo Nordisk, as a treatment for chronic weight management in 2021. It has since exploded in popularity

What's News

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Subscribe Now

Already a subscriber? Sign In

Sponsored Offers
  • AT&T:
    Get a $50 reward card using this AT&T promo code
  • Walmart:
    20% off your order with Walmart promo code
  • Best Buy:
    Deal of the Day! Claim as much as 50% off - Best Buy coupon
  • Target:
    Target Promo Code: 20% off Entire Order
  • Vitacost:
    Take 15% OFF all Foods with Vitacost Promo Code